Objective The third generation drug eluting Orsiro stent had shown already promising results in non-complex lesions. Background We evaluated angiographic and 24 month clinical results of the sirolimus eluting Orsiro… Click to show full abstract
Objective The third generation drug eluting Orsiro stent had shown already promising results in non-complex lesions. Background We evaluated angiographic and 24 month clinical results of the sirolimus eluting Orsiro stents (O-SES) after recanalization of coronary chronic total occlusions (CTO). Results were compared with the zotarolimus eluting Resolute Integrity (R-ZES). Methods In a prospective series 57 patients were treated with a R-ZES followed by 74 patients treated with a O-SES stent. Angiographic follow up after 9 months and clinical follow-up after 12 and 24 months was performed. Results In-stent late lumen loss was 0.24±0.53 mm for the O-SES compared with 0.59±0.72 (P=0.01) for R-ZES. Rates for TLR were similar (O-SES 10.0% versus R-ZES 11.1%, P=0.84). There was no definite stent thrombosis. Conclusion The O-SES resulted in a significant lower late lumen loss but with similar clinical results up to 24 month compared to the R-ZES after treatment of CTO lesions.
               
Click one of the above tabs to view related content.